交银国际(03329)发布公告，谭岳衡先生因工作调整原因辞任公司执行董事，自2026年1月1日起生效。 于其辞任后，谭先生将自动终止担任董事会战略及风险管理委员会委员。 ...

智通财经APP讯，交银国际(03329)发布公告，谭岳衡先生因工作调整原因辞任公司执行董事，自2026年 1月1日起生效。于其辞任后，谭先生将自动终止担任董事会战略及风险管理委员会委员。 ...

非執行董事 肖霆先生 （董事長） 朱忱女士 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 （於香港註冊成立的有限公司） （股份代號：3329） 董事名單及其角色與職能 交銀國際控股有限公司董事會成員載列如下，自2026年1月1日起生效： 相關董事會附屬委員會成員載列如下： | 董事 | 戰略及風險 管理委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 肖霆先生 | C | | | | | 朱忱女士 | M | | M | M | | 謝潔先生 | M | | | | | 王賢家先生 | M | | | | | 馬宁先生 | | M | M | C | | 林志軍先生 | | C | M | M | | 浦永灝先生 | | M | C | M | 附註： C 委員會主席 M 委員會成員 香港，2025年12月31日 執行董事 謝潔先生 （首席執行官） 王賢家先生 （副行政總裁、首席風險官） 獨立非執行董事 馬宁先生 林志軍先生 浦永灝先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 執行董事辭任 交銀國際控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）宣佈，譚岳衡先生 （「譚先生」）因工作調整原因辭任本公司執行董事，自2026年1月1日起生效。於其辭任 後，譚先生將自動終止擔任董事會戰略及風險管理委員會委員。 譚先生已確認，彼與董事會並無意見分歧，亦無有關其辭任的事宜須提請本公司股東垂 注。 董事會謹藉此機會對譚先生於其任期內對本公司作出的寶貴貢獻致以衷心感謝。 承董事會命 交銀國際控股有限公司 公司秘書 曾佳荔 香港，2025年12月31日 （於香港註冊成立的有限公司） （股份代號：3329） 於本公告日期，董事會包括非執行董事肖霆先生及朱忱女士；執行董事謝潔先生、 王賢家先生及譚岳衡先生；及獨立非執行董事馬宁先生、林志軍先生及浦永灝先生。 ...

Group 1 - The technology sector is currently active, with the Huatai-PineBridge AI ETF (159139) showing a slight increase of 0.1% and a trading volume exceeding 20 million yuan, indicating active market participation [1] - The ETF tracks the CSI Innovation and Entrepreneurship AI Index, which was launched on December 19 and consists of 50 leading companies focused on AI technology development, hardware support, and commercial applications in vertical fields [1] - According to Jiyin International, the demand for artificial intelligence is expected to remain high, with capital expenditures from major overseas cloud providers projected to grow by over 60% year-on-year in 2024 and 2025, and an additional growth of over 30% in 2026 [1] Group 2 - CITIC Securities highlights that the world is currently undergoing an AI industrial revolution, which has far-reaching implications and should be observed from a long-term perspective, unlike recent trends in cloud computing and renewable energy [2] - The demand for computing power driven by AI is expected to be significant, with B-end applications, such as programming, likely to be the first areas for industrialization and monetization [2] - The successful commercialization and closed-loop of large AI models will require substantial investment in computing power, suggesting a focus on core large model companies [2]

Core Viewpoint - A trend of "counter-market buying" is emerging in the Hong Kong stock market amidst ongoing fluctuations, with institutional investors recognizing the valuation opportunities and actively seizing the market pullback as a layout window [1][4]. Group 1: Fundraising and Investment Trends - Since October 10, at least 15 new Hong Kong-themed funds have announced early fundraising closures, covering various types including passive index funds, equity mixed funds, and QDII funds [2]. - The early fundraising trend is characterized by significantly shortened timelines, with some funds reducing their fundraising periods by over a month [2]. - Newly launched ETFs have established high stock positions quickly, indicating strong bullish signals, with some ETFs reaching stock positions of 69.53% and 63.32% before listing [3]. Group 2: Market Conditions and Valuation - The recent market adjustment has provided a favorable entry point for new funds, as many heavy-weight stocks have seen significant weekly declines while maintaining stable fundamentals [4]. - The Hang Seng Index's price-to-earnings ratio (TTM) is approximately 12 times, and the Hang Seng Tech Index's is about 23 times, both at historical low levels, reflecting institutional recognition of undervalued Hong Kong stocks [5]. Group 3: Market Challenges - The Hang Seng Index has dropped 5.85% and the Hang Seng Tech Index has fallen 18.01% since October 3, indicating a clear market correction [6]. - Factors contributing to the market adjustment include fluctuating liquidity expectations, concerns over the "AI bubble" in the U.S., increased IPO activity, and reduced southbound capital inflows [7][8]. Group 4: Long-term Outlook and Investment Opportunities - Despite short-term pressures, institutions maintain an optimistic long-term outlook for the Hong Kong stock market, predicting a "slow bull" market in 2026 with improved liquidity conditions [9]. - Key investment themes for 2026 include technology and high-end manufacturing, with a focus on sectors such as computing power, semiconductors, and consumer electronics [9]. - High dividend yield assets are also favored in a low-interest-rate environment, with institutions highlighting the value of leading copper and aluminum mining companies [9]. - The innovative drug and biotechnology sectors are seen as having significant investment opportunities due to industry acceleration and favorable policy adjustments [10].

Core Viewpoint - A trend of "counter-market buying" is emerging in the Hong Kong stock market amidst ongoing fluctuations, with institutional investors recognizing the valuation opportunities and actively positioning themselves during the market pullback [1][3]. Fundraising and Investment Trends - Since early October, at least 15 new Hong Kong-themed funds have announced early closures of their fundraising periods, particularly in the technology sector, indicating a "fast launch and build" characteristic [1][2]. - Fundraising deadlines have been significantly advanced, with some funds shortening their periods by over a month, reflecting a concentrated early closure trend primarily occurring from late November to mid-December [2]. - Newly launched ETFs have established high stock positions quickly, with notable examples including the Huatai-PineBridge Hang Seng Index ETF and the GF CSI Hong Kong Internet ETF, which reached stock positions of 69.53% and 63.32% respectively before listing [2]. Market Analysis and Institutional Sentiment - Institutions view the current market adjustment as a favorable opportunity for building positions, with many believing that the recent declines provide lower entry points for fundamentally strong companies [3]. - The Hang Seng Index's price-to-earnings ratio (TTM) is approximately 12 times, and the Hang Seng Technology Index's is about 23 times, both at historically low levels, indicating a consensus among institutions regarding the undervaluation of Hong Kong stocks [3]. Market Conditions and External Influences - The Hong Kong stock market has experienced a decline of 5.85% in the Hang Seng Index and 18.01% in the Hang Seng Technology Index from October 3 to December 19 [5]. - The market adjustment is attributed to a combination of internal and external factors, including fluctuating liquidity expectations, concerns over the U.S. "AI bubble," increased IPO activity, and reduced southbound capital inflows [6]. Long-term Outlook and Investment Opportunities - Despite short-term pressures, institutions maintain an optimistic long-term outlook for the Hong Kong stock market, predicting a "slow bull" market in 2026 with improved liquidity conditions [7]. - Key investment themes for 2026 include technology and high-end manufacturing, with a focus on sectors such as computing power, semiconductors, and consumer electronics [7][8]. - High dividend yield assets are also favored in the current low-interest-rate environment, with institutions highlighting the value of dividend-paying stocks [7]. - The innovative drug and biotechnology sectors are seen as having significant investment opportunities, driven by industry acceleration and favorable policy adjustments [8].

Group 1 - The core viewpoint of the report is that there is a trend of increasing domestic innovative drug transactions as the year-end approaches, with a positive outlook for value recovery by 2026 [1] - Since October, the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect has slightly decreased, while foreign investment remains stable, indicating a continued focus on innovative drug layouts by both domestic and foreign investors [1] - This week, multiple business development (BD) transactions exceeding $1 billion have been completed, involving both multinational corporations (MNCs) and small to medium-sized biotech companies, suggesting a concentration of new BD opportunities as the year ends [1] Group 2 - The report recommends focusing on specific segments: 1) Innovative drugs such as 3SBio (01530), Eucure Biopharma (06996), and BeiGene (06160), which have rich catalysts and valuations that do not yet reflect the core value of major products; 2) CXO companies like WuXi AppTec (02269) that benefit from high downstream demand and marginal recovery in financing; 3) Hospital, medical device, and diagnostics sectors that may have reversal opportunities as regulatory uncertainties gradually ease [2]

Core Viewpoint - The company, Jiao Yin International (03329), held a special shareholders' meeting on December 17, 2025, where three ordinary resolutions were approved, including the renewal of property leasing agreements and new financial service frameworks until December 31, 2028 [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting resulted in the approval of three ordinary resolutions with a voting outcome of 99.999314% in favor, representing 145,785,167 shares, while only 0.000686% opposed, equating to 1,000 shares [1] - The resolutions included the approval, ratification, and confirmation of an automatic renewal property leasing framework agreement for three years until December 31, 2028, along with the approval of new financial service and fintech service framework agreements for the same period [1] - The voting was conducted by Hong Kong Central Securities Depository Limited, and due to related party transactions, the controlling shareholder, Bank of Communications, which holds approximately 73.14% of the company, abstained from voting [1] Group 2: Stock Performance - As of the close on December 18, 2025, Jiao Yin International's stock price was 0.36 HKD, reflecting a decrease of 1.37% from the previous trading day, with a trading volume of 458,200 HKD [1] - The stock has experienced a 52-week high of 1.08 HKD and a low of 0.25 HKD, indicating significant volatility in its market performance [1]

Group 1 - The core viewpoint of the report is that after a recent stock price correction, valuations of certain leading photovoltaic companies have become attractive, with a particular focus on polysilicon as a benchmark for "anti-involution" [1] - The report highlights that the preferred choice is the leading granular silicon company, GCL-Poly Energy Holdings Limited (03800), and also favors the undervalued rod silicon leader, Xinte Energy Co., Ltd. (01799), which is expected to benefit more from capacity consolidation [1] - The recent Central Work Conference emphasized the need for deeper regulation of "involution-style" competition, marking a shift from "comprehensive regulation" to "in-depth regulation," which suggests that substantial capacity reduction policies may gradually be introduced [1] Group 2 - The establishment of a polysilicon capacity consolidation platform has been officially completed, as reported by the China Photovoltaic Industry Association, indicating a significant step in the long-anticipated integration of the photovoltaic industry [1] - Beijing Huaguang Qiancheng Technology Co., Ltd. has completed its registration, marking the formal launch of the "polysilicon capacity integration acquisition platform" [1]